



**IMDRF**

International Medical  
Device Regulators Forum

# **Personalized Medical Devices Working Group 2020 Update**

**Tracey Duffy**

**First Assistant Secretary**

**Medical Devices and Product Quality Division**

**Therapeutic Goods Administration—Department of Health**

**September 2020**



## Working group overview

### Working group rationale:

Technology has progressed to where it is now possible to 'mass produce' individualised medical devices, for example, 3D-printing of devices based on patient CT scan data.

Original GHTF documentation does not adequately address these types of devices.



[Working Group Meeting in Canberra](#)  
[October 2019](#)

### Work item timeline

2018

November 2018: Published N49—  
Definitions for Personalized Medical  
Devices

2020

March 2020: Published N58—  
Personalized Medical Devices—  
Regulatory Pathways (Approved)

TBD

Proposed NWIE—Personalized  
Medical Devices—Considerations for  
validating design envelopes and  
personalized medical device  
production systems



## Benefits of reform

- Addresses an emerging trend towards personalized treatments in the medical devices sector.
- Ensures an appropriate level of regulatory oversight is undertaken.
- Leads to harmonisation of requirements for safety, performance and manufacturing of these products.
- Provides a basis for consistent and transparent requirements across multiple jurisdictions.
- Aligns with IMDRF Strategic Priorities.




## Final regulatory pathways document (N58)

The goal of this project was to develop a technical document that provides recommendations to support a harmonised approach to regulating medical devices that are manufactured for individuals.


- Two-month public consultation held 24 May 2019 through 24 July 2019
- 17 submissions including from Australia, Canada, Europe, Singapore, Taiwan, USA
- 150 Individual comments
- Working group meeting in Canberra October 2019 to review comments and update the document
- Final document delivered and agreed by IMDRF Management Committee

Published March 2020





## Regulatory pathways





# Regulatory pathways

## Custom-made medical devices

- Highest level of detail
- Recognises unique pathway for custom-made devices

## Patient-matched medical devices

- Reliance on usual regulatory requirements, according to the device regulatory classification
- Focus on validation of design envelope

## Adaptable medical devices

- Reliance on usual regulatory requirements, according to the device regulatory classification
- Focus on validated instructions for the adaptable features

## Medical device production system (MDPS)

- Considered to be a medical device in its own right
- Reliance on usual regulatory requirements, according to the device regulatory classification of device produced
- Focus on validation of production process



## Annexes

### Annex 1—Additive and subtractive manufacturing considerations

- Introduces MDPS
- Clarifies status of raw materials for additive manufacture vs materials that are medical devices

### Annex 2—Considerations for point-of-care manufacture

- Manufacturing under special arrangements (e.g. exemptions)
- Using medical device production systems
- Fully regulated manufacturing as per the GHTF/IMDRF model



**IMDRF**

International Medical  
Device Regulators Forum

## **Next steps—PMD validation guidance**

- for consideration by the IMDRF Management Committee in 2020





**IMDRF**

International Medical  
Device Regulators Forum

Thank you